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Poly(ADP-ribose) polymerases (PARPs) are a family of enzymes that catalyze the
addition of poly(ADP-ribose) (PAR) subunits onto themselves and other acceptor
proteins. PARPs are known to function in a large range of cellular processes including
DNA repair, DNA replication, transcription and modulation of chromatin structure.
Inhibition of PARP holds great potential for therapy, especially in cancer. Several
PARP1/2/3 inhibitors (PARPi) have had success in treating ovarian, breast and prostate
tumors harboring defects in the homologous recombination (HR) DNA repair pathway,
especially BRCA1/2 mutated tumors. However, treatment is limited to specific sub-
groups of patients and resistance can occur, limiting the use of PARPi. Poly(ADP-ribose)
glycohydrolase (PARG) reverses the action of PARP enzymes, hydrolysing the ribose-
ribose bonds present in poly(ADP-ribose). Like PARPs, PARG is involved in DNA
replication and repair and PARG depleted/inhibited cells show increased sensitivity to
DNA damaging agents. They also display an accumulation of perturbed replication
intermediates which can lead to synthetic lethality in certain contexts. In addition, PARG
is thought to play an important role in preventing the accumulation of cytoplasmic PAR
and therefore parthanatos, a caspase-independent PAR-mediated type of cell death. In
contrast to PARP, the therapeutic potential of PARG has been largely ignored. However,
several recent papers have demonstrated the exciting possibilities that inhibitors of this
enzyme may have for cancer treatment, both as single agents and in combination
with cytotoxic drugs and radiotherapy. This article discusses what is known about the
functions of PARP and PARG and the potential future implications of pharmacological
inhibition in anti-cancer therapy.
Keywords: poly(ADP-ribose)polymerase (PARP), poly(ADP-ribose)glycohydrolase (PARG), synthetic lethality,
chemosensitization, radiosensitization, cancer
Abbreviations: altEJ, alternative non-homologous end-joining; ARH, ADP-ribose hydrolases; ART, (ADP-
ribosyl)transferase; CHK2, checkpoint protein 2; DSBR, double strand break repair; DSBs, double strand breaks;
HR, homologous recombination; HU, hydroxyurea; IR, ionizing radiation; MAR, mono(ADP-ribose); NAD+,
nicotinamide adenine dinucleotide; NHEJ, non-homologous end-joining; PAR, poly(ADP-ribose); PARG, Poly(ADP-
ribose) glycohydrolase; PARGi, PARG inhibitors; PARP, poly(ADP-ribose) polymerase; PARPi, PARP1/2/3 inhibitors; SAM,
sterile alpha module; SSBR, single strand break repair; SSBs, single strand breaks; TIPs, tankyrase interacting proteins;
TNK, Tankyrase.
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INTRODUCTION
Poly(ADP-ribose) polymerases (PARPs) are a superfamily of
multi-domain proteins each possessing a highly conserved
(ADP-ribosyl)transferase (ART) domain that catalyzes the
cleavage of nicotinamide adenine dinucleotide (NAD+) into
nicotinamide and ADP-ribose (Chambon et al., 1963, 1966;
Nishizuka et al., 1967; Sugimura et al., 1967; Hayaishi and
Ueda, 1977; Okayama et al., 1977). The ADP-ribose unit is
then transferred to an acceptor protein, or itself, on specific
amino acid residues (glutamate, lysine, arginine, serine, and
aspartate, and also more recently reported cystine, threonine,
histidine, tyrosine, and phospho-serine (through the phosphate)
(Vyas et al., 2014; Hendriks et al., 2019) (Figure 1). This
transfer can occur in a monomeric or polymeric (linear
or branched chain) manner depending on the particular
PARP enzyme (Miwa and Sugimura, 1971; Miwa et al.,
1979; Rolli et al., 1997; Ruf et al., 1998). The ADP-ribose
moieties are generally considered to be added to the most
distal ADP-ribose terminus (Taniguchi, 1987; Alvarez-Gonzalez,
1988), however, other models have been suggested (Ikejima
et al., 1987). Poly(ADP-ribose) glycohydrolase (PARG) and
other mono(ADP-ribose) (MAR) and poly(ADP-ribose) (PAR)
erasers such as ADP-ribose hydrolases (ARHs), macrodomain-
containing ADP-ribose erasers, and ADP-ribosyl lyase are
responsible for the rapid removal of ADP-ribose moieties
from modified proteins, thus recycling NAD+ back into the
cellular system (Figure 1). The primary focus of this review
is PARG, however, to facilitate understanding, it is important
to place it in the context of PARP activity, function and
therapeutic inhibition.
THE STRUCTURE AND ENZYMATIC
ACTIVITY OF THE PARP (ARTD) FAMILY
The PARP family consists of at least 17 members, classified
by domain structure or activity. PARPs1-5b share a conserved
His-Tyr-Glu (H-Y-E triad) within the NAD+ binding pocket of
the ART domain (Otto et al., 2005). This triad is predicative
of PARylation capabilities. Of these enzymes PARP1 was the
first to be discovered (Chambon et al., 1963, 1966; Nishizuka
et al., 1967; Sugimura et al., 1967) and is the most intensely
researched. PARP1 is classified as a nuclear DNA activated
PARylator, capable of adding multiple ADP-ribose residues to
a single acceptor. These PAR units have been reported up to
hundreds of residues in size. Furthermore, PARP1 is capable of
promoting branching within a growing PAR chain (Miwa and
Sugimura, 1971; Miwa et al., 1979; Rolli et al., 1997; Ruf et al.,
1998). PARP2 is considered to have similar activity to PARP1
(Miwa et al., 1979; Rolli et al., 1997; Ruf et al., 1998). Both PARP1
and 2 are capable of catalyzing multiple activities from the ART
domain, i.e., the initial transfer of ADP-ribose to an acceptor
protein, elongating this chain further by catalyzing a 2′–1′′ ribose-
ribose glycosidic bond and instigating branching by catalyzing a
2′′–1′′′ ribose-ribose bond (Figure 1). Both PARP1 and PARP2
are activated by DNA damage, with different lesions reported
to activate activity to varying degrees (Benjamin and Gill, 1980;
Amé et al., 1999; Eustermann et al., 2015). PARP3 is also
activated by DNA damage, however, despite containing the H-Y-
E triad, there is conflicting evidence regarding its MARylation
and PARylation activity. Initially, PARP3 was considered only
capable of MARylation, however, it is now known to PARylate
NuMa (Boehler et al., 2011) and KU80 (Beck et al., 2014). In
addition to modifying proteins, PARP3 can also MARylate and
PARylate free double strand break (DSB) ends (Munnur and
Ahel, 2017; Zarkovic et al., 2018). The ability to carry out mono-
and poly(ADP-ribosyl)ation may be reflective of a more complex
and nuanced role of PARP3 in different cellular processes. PARP4
is associated with the vault complex, a massive ribonucleoprotein
complex of unclear function and has MARylation activity (Van
Zon et al., 2003). PARP5a and 5b, also known as tankyrases 1
and 2 (TNK1 and TNK2), are not dependent on DNA damage
for catalytic activation and are located more widely throughout
the cell (Cook et al., 2002). They are also capable of PARylation
activity, typically only producing oligomers up to 20 ADP-ribose
residues in length (Rippmann et al., 2002). The significance
of PAR length and size is not fully understood. The rest of
the family (PARP6-17) are considered MARylaters (Bai, 2015),
with PARP9 only showing activity when complexed to DTX3L
(Yang et al., 2017). However, PARP13 does not possess catalytic
activity (Vyas et al., 2014). The PARP name is therefore a
misnomer. The family’s expansion and previous nomenclature
inaccuracies/inconsistencies has resulted in a new nomenclature
proposal (Hottiger et al., 2010). This nomenclature revolves
around the enzymatic reaction (ART) and enzymatic structural
markers (diphtheria-like, in reference to the presence of the H-Y-
E triad motif in secreted ADP-ribosylating pathogenic diphtheria
toxins by Corynebacterium diphtheriae), hence the name ARTD.
However, for clarity and consistency with the literature the PARP
nomenclature will be used here. As the focus of this review is
PARG which reverses PARylation and not MARylation (Slade
et al., 2011), the function of the PARP enzymes capable of
PARylation will be briefly discussed.
THE FUNCTIONS OF PARylating
ENZYMES
Poly(ADP-Ribose) Polymerase 1, 2, and 3
PARP1, 2, and 3 contain DNA binding domains that facilitate
their interaction with DNA and enable them to PARylate target
proteins, perform auto-modification and even modify free DNA
ends (Vyas et al., 2014). PARylation has been observed to
have multiple context dependent consequences. One is that the
modified proteins operate as a recruitment platform for other
proteins. For example, efficient resolution of single strand breaks
(SSBs) is facilitated by XRCC1 (Whitehouse et al., 2001), the
recruitment of which is in turn enhanced by interaction with
DNA bound automodified PARP1 and 2 at sites of damage
(Masson et al., 1998; Okano et al., 2003; Fisher et al., 2007;
Hanzlikova et al., 2016). Additional consequences of PARylation
on an acceptor protein include DNA/RNA dissociation due to
the strong negative charge of PAR (Satoh and Lindahl, 1992),
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FIGURE 1 | Overview of the PAR Cycle. PARP family enzymes use NAD+ as a substrate to catalyze the transfer of an ADP-ribose moiety to a receptive carboxyl
group on an aspartate, glutamate, asparagine, arginine, or lysine residue of an acceptor protein. Nicotinamide is cleaved off in the reaction. The
mono-ADP-ribosylated protein is referred to as being MARylated. PARPs 1-5 are also capable of catalyzing the addition of ADP-ribose to distal ADP-ribose residues
forming a polymer of ADP-ribose – PAR, through 2′–1′′ ribose-ribose glycosidic and 2′′–1′′′ ribose-ribose glycosidic bonds. PARG is an endo- and exoglycosidase, it
catalyses PAR releasing free poly(ADP-ribose) and ADP-ribose. However, PARG cannot remove the most proximal ADP-ribose. This is removed by other ADP-ribose
hydrolases (ARH). The resulting free ADP-ribose is catalyzed by ADP-ribose pyrophosphohydrolases such as the NUDIX family producing ribose-5-phosphate (R5P)
and Adenine-mono-phosphate (AMP). They are used in the production of biomolecules and metabolism.
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and acceptor protein topography changes influencing protein-
protein interactions or modulating acceptor protein catalytic
activity (Muthurajan et al., 2014; Fischbach et al., 2018; Zhen
and Yu, 2018; Yang et al., 2020). Finally PARPs are reported
to MARylate and PARylate DNA/RNA ends directly, although
the functional consequence of this is not clear (Audebert et al.,
2004; Wang et al., 2006; Fisher et al., 2007; Gao et al., 2007;
Haince et al., 2008; Talhaoui et al., 2016; Munnur and Ahel, 2017;
Zarkovic et al., 2018; Munnur et al., 2019). Through these modes
of action, PARylation by PARP1 and/or 2 has been reported
to influence multiple pathways of DNA repair including, single
strand break repair (SSBR) (Fisher et al., 2007; Hanzlikova et al.,
2016), homologous recombination (HR) (Haince et al., 2008),
non-homologous end-joining (NHEJ) (Wang et al., 2006), and
alternative non-homologous end-joining (alt-EJ) (Audebert et al.,
2004) (Figure 2). They are also required for DNA replication
FIGURE 2 | Models of PARP function at single and double strand breaks. Potential sites where PARG function is required to reverse PARylation to facilitate
downstream processing are indicated by PARG?, proven roles indicated by PARG. (A) SSBs, arising directly from damage to the DNA backbone or as intermediates
in BER, are bound by PARP1 or PARP2. DNA binding activates PARP causing automodification. Automodified PARP recruits XRCC1 to the SSB. PARP is displaced.
Damaged 5’- or 3’-termini are processed into 5’-phosphate and 3’-hydroxyl groups by APE1 or PNK. Polβ then performs gap filling followed by ligation by Lig3α.
(B,C) PARP activity regulates the relative contribution that non-homologous end-joining (NHEJ) and homologous recombination (HR) make to repair of DNA double
strand breaks (DSBs). NHEJ begins with binding of the DNA ends by the Ku70/80 heterodimer, which recruits DNA-PKcs. If the ends are not compatible, they are
trimmed by nucleases, e.g., Artemis. The ligation complex XRCC4-DNA Ligase IV-XLF then seals the DSB. In HR, MRE11 resects the break to generate single
stranded DNA (ssDNA), which is quickly coated and subsequently replaced by Rad51. The Rad51 nucleoprotein filaments mediate strand invasion of the
homologous template. Synthesis of DNA using the sister chromatid is then followed by capture of the second end and holiday junction (HJ) resolution or dissolution
leading to DSB repair. PARP1 competes with KU for binding at DSBs and promotes resection by MRE11 (a component of the MRN complex, therefore PARP1
activation favors HR. In contrast PARP3 PARylates KU70/80and limits DNA end resection favoring NHEJ. TNK1/2 PARylates CHK2 to promote HR. (D) PARP1 is
required to recruit MRE11 to regions of DNA micro-homology in order to initiate alternative end-joining (alt-EJ), following limited resection and strand annealing, the
DNA flaps are cleaved, finally Pol q and the ligation complex XRCC1-ligase III seal the gap.
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fork stability under conditions of replication stress (Figure 3)
(Sugimura et al., 2008; Bryant et al., 2009; Petermann et al.,
2010; Min et al., 2013; Ying et al., 2016). PARP1 is thought to
account for approximately 90% of the cell’s PARylation activity.
However, PARylation still occurs in PARP1 deficient cells (Shieh
et al., 1998; Beneke et al., 2000; Dantzer et al., 2000; Masutani
et al., 2000) suggesting that PARP1 and 2 have overlapping
roles and that PARP2 may be able to partially compensate
for PARP1 loss. For example, both are capable of recruiting
XRCC1 to chromatin for SSBR (Fisher et al., 2007; Hanzlikova
et al., 2016), promoting nucleolar transcription via a mutual
interaction with B23 (Meder et al., 2005), possessing partially
overlapping interactomes (Isabelle et al., 2010) and both engaging
in replication fork stabilization (Ronson et al., 2018). Supportive
of compensatory roles, co-deletion of PARP1 and PARP2 results
in embryonic lethality (Menissier De Murcia, 2003), however,
FIGURE 3 | Models of PARP function at replication forks. Potential sites where PARG function is required to reverse PARylation to facilitate downstream processing
are indicated by PARG? (A) PARP is activated at stalled replication forks and poly(ADP-ribosyl)ates RECQ1 thus constraining its branch migration activity. In addition
PARP binds and protects stalled forks form excessive nuclease activity. (B,C) PARP activation occurs at collapsed replication forks or gaps in the lagging strand
post-replication, in each case promoting MRE11 to resect the leading strand template allowing for HR–mediated fork recovery. (D) PARP can recruit XRCC1 and
DNA-PK to stalled reversed replication forks. However, only a small defect in the restart of stalled forks is seen when PARP activity is absent, suggesting this function
is to mediate repair of a subset of stalled forks, perhaps where small lesions impede re-start of the forks (E) PARP can bind to and is activated at unligated Okazaki
fragments during DNA replication, promoting recruitment of XRCC1 and ligase III thus facilitating repair and continued replication.
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PARP1−/−mice exhibit increased spontaneous tumor incidence
suggesting PARP2 cannot fully compensate for PARP1 loss
(Shibata et al., 2009). In contrast to PARP1/PARP2 double
knockout mice, PARP1/PARP3 knockout animals are viable
suggesting a separate function for PARP3 (Boehler et al., 2011).
However, this does not exclude a separate role for PARP3 in DNA
repair, especially as the PAR activity of PARP3 is activated by
different types of breaks to PARP1 (Langelier et al., 2014). In
this regard PARP3 is implicated in DNA double strand break
repair (DSBR) where it may work in concert with PARP1 to help
coordinate repair by classical non-homologous end-joining (c-
NHEJ) (Figure 2) (Boehler et al., 2011; Rulten et al., 2011; Fenton
et al., 2013; Beck et al., 2014). Outside of DNA repair, nuclear
PARPs have also been implicated in transcription, chromatin
modification and cell death pathways (Yu et al., 2006; Szántó
et al., 2012; Dantzer and Santoro, 2013; Muthurajan et al., 2014).
Interestingly, the balance between auto- and trans-ribosylation is
suggested to play a role in regulating PARP function, with trans-
modification of histones limiting auto-modification of PARP1/2
in a HPF1 dependent fashion (Gibbs-Seymour et al., 2016;
Palazzo et al., 2018; Suskiewicz et al., 2020).
In summary, PARP1-3 are all localized to the nucleus, each
is activated by free DNA ends and is implicated in many
cellular processes to varying degrees. One of the key ways in
which PARP1-3 function is via the addition of a large post-
translational modification onto themselves and other proteins.
PARG functions to reverse this modification and thus absence or
inhibition of PARG is likely to alter the kinetics of dePARylation,
leaving proteins inappropriately modified. This is likely to have a
similarly complex, overlapping and, perhaps also a unique set of
consequences as the lack of PARylation induced by PARPi.
For more comprehensive reviews of PARP1-3 biology (see Bai,
2015; Gupte et al., 2017; Ray Chaudhuri and Nussenzweig, 2017).
The Tankyrases – PARP 5a and 5b
Tankyrase 1 (TNK1) and tankyrase 2 (TNK2) (also known as
PARP5a and 5b) are a distinct subgroup of the PARPs found
in the nucleus, golgi apparatus, cytoplasm and at telomeres
[reviewed in Kim (2018)]. They are capable of homo and hetero
dimerization via their sterile alpha module (SAM) domain and
can be activated and auto-modified in a DNA independent
manner. Both produce oligomers of ADP-ribose typically up
to 20 units in length (Smith, 1998; Rippmann et al., 2002;
De Rycker and Price, 2004). TNK1 and TNK2 are considered
scaffold proteins; they contain 24 ankyrin domains, divided
into 5 ankyrin (ANK) repeat clusters (ARC) that individually
are capable of binding to tankyrase interacting proteins (TIPs).
Many of the TIPs are also substrates of TNK1 and TNK2. TIPs
are a diverse group of proteins spanning numerous cellular
processes. Consistent with this, tankyrases have reported roles in
DNA repair, including stabilizing and PARylating DNA-PK and
checkpoint protein 2 (CHK2) (Dregalla et al., 2010; Nagy et al.,
2016; Okamoto et al., 2018), telomerase-dependent telomere
length maintenance (Smith, 1998; Smith and De Lange, 2000),
spindle assembly, centrosome maturation, resolution of sister
telomeres during mitosis (Dynek and Smith, 2004; Chang et al.,
2005, 2009; Canudas et al., 2007; Ozaki et al., 2012), Wnt, Notch,
AKT and YAP signal transduction pathways (Huang et al., 2009;
Li et al., 2015; Mariotti et al., 2016, 2017; Troilo et al., 2016;
Yang et al., 2016; Jia et al., 2017), and regulation of glucose
metabolism (Chi and Lodish, 2000; Yeh et al., 2009; Zhong
et al., 2016). Most tankyrase functions are considered to be
mediated via PARylation, altering protein:protein interactions.
Often but not exclusively, tankyrase-mediated PARylation is
recognized and ubiquitinated by the E3 ligase RNFL146 (Zhang
et al., 2011), this targets substrates for proteasomal degradation
and thus regulation is commonly via alteration of protein
stability. However, evidence is also emerging that tankyrases can
have catalytic independent functions (Pollock et al., 2019). As
tankyrase biology is relatively less well understood than that of
PARP1-3, it is likely that further, unknown tankyrase functions
exist. The ankyrin domains within TNK1 and TNK2 share 83%
homology and it is thought that many of the TIPs overlap. Where
investigated this has been confirmed to be the case; indeed double
tankyrase knockout is embryonic lethal whereas single tankyrase
knockout mice have different yet mild phenotypes (Chiang et al.,
2006, 2008; Hsiao et al., 2006). This implies distinct interacting
partners and functions exist. It is suggested that PARG inhibition
will prevent removal of tankyrase catalyzed-PAR, thus inhibition
of PARG is likely to impinge on many tankyrase regulated
pathways (Gravells et al., 2018). However, this activity for PARG
has not been formally demonstrated.
PARP INHIBITION (PARPi)
PARP Inhibitors
Inhibition of PARPs can be mediated by small molecules
containing nicotinamide/benzamide pharmacores that dock into
the NAD+ pocket within the ART domain. Here they act
as competitive inhibitors of NAD+, preventing ADP-ribose
transferase activity (Preiss et al., 1971; Durkacz et al., 1980;
Purnell and Whish, 1980; Marsischky et al., 1995; Canan Koch
et al., 2002; Skalitzky et al., 2003; Calabrese et al., 2004;
Ferraris, 2010). Conservation within the catalytic pocket makes
specific inhibition of PARPs challenging and despite multiple
sophisticated drug discovery programs even many of the latest
and clinically relevant PARP1/2 inhibitors are not completely
selective, with inhibition of PARP3 and tankyrases being the
most common targets of cross-reactivities (Carney et al., 2018).
The cytotoxicity of PARP inhibition is considerably greater
than loss of PARP; an explanation for this is that catalytically
inactive PARP can become “trapped” on DNA (Satoh and
Lindahl, 1992; Murai et al., 2012). As inhibitors with similar
inhibitory activities display different trapping abilities (Murai
et al., 2014), it has been proposed that interactions between
an inhibitor and the PARP NAD binding domain can lead
to allosteric interactions within the DNA binding domain of
PARP, tightening the interaction between PARP and DNA
(Langelier et al., 2018). Furthermore, once bound to DNA
in the presence of an inhibitor, PARP is “trapped” because
inhibition of catalytic activity prevents the auto-ribosylation
that promotes PARP-DNA dissociation (Shen et al., 2015;
Langelier et al., 2018).
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The therapeutic contribution of relative trapping potencies
and specificity of each inhibitor against PARP1/2/3/5a and 5b
proteins is yet to be fully determined. Whether PARP1-3 and
TNK1/2 are trapped on DNA when PARG is inhibited is yet to be
fully determined but will likely influence the potency of PARGi.
PARPi Sensitize to DNA Damaging
Agents
The characterization of PARP1’s involvement in DNA repair
quickly led to the realization that inhibitors may potentiate
the standard treatment modalities employed in oncology, such
as DNA damaging agents, particularly temozolomide, and
radiotherapy (Durkacz et al., 1980; Sakamoto et al., 1983;
Arundel-Suto et al., 1991; Suto et al., 1991; Banasik et al., 1992;
Satoh and Lindahl, 1992; Griffin et al., 1995; Bowman et al.,
1998; Calabrese et al., 2004). Drug discovery pipelines eventually
produced more clinically viable inhibitors with greater potency,
specificity, drug solubility and bioavailability (Curtin, 2014) and
the first clinical trial was a combination of the PARPi rucaparib
and temozolomide (Plummer et al., 2008). There are currently
many clinical trials being undertaken with different inhibitors
of PARP namely olaparib, rucaparib, veliparib, niraparib, and
talazoparib, in a range of cancers (De Bono et al., 2017; Jiang et al.,
2019; Tuli et al., 2019), and their capacity to act as chemo/radio-
sensitizers is well documented. A comprehensive review of
PARP inhibitor development for cancer including stratification
of patients, biomarker identification and combination strategies
can be found here (Davar et al., 2012; Mateo et al., 2019).
PARPi Is Synthetically Lethal With
Defects in Homologous Recombination
In cells with loss of function mutations associated with breast
cancer susceptibility genes BRCA1 or 2, inhibition of PARP
was demonstrated to be synthetically lethal (Bryant et al.,
2005; Farmer et al., 2005). Bryant et al. (2005) extended their
study to include other genes involved in HR suggesting the
mechanism stems from a relationship between PARP and the
HR pathway. This observation has resulted in a paradigm shift
andmany other synthetically lethal relationships including others
with PARP, have been described (Turner et al., 2008). The
mechanism of action underpinning the sensitivity of BRCA
mutated cells to PARP1 inhibition is thought to be multifactorial
(Dziadkowiec et al., 2016). PARylation by PARP1 and 2 is
involved in SSBR, the protection of replication forks and fork
restart (Figures 2, 3). Therefore, catalytic inhibition can lead to
an increase in unresolved DNA lesions and stalled forks that can
collapse and then translate to DSBs in DNA. PARP inhibitors
can also cause PARP to be “trapped” on DNA (Murai et al.,
2012). This trapped protein is itself a form of DNA lesion, thus
when trapped PARPs collide with replication forks, this can
stall replication forks and may produce DSBs, which is likely
to compound the potency of those PARPi with greater trapping
ability. HR is required to resolve DSBs, andmanyHR proteins are
also required for fork protection/restart during replication stress
(Slack et al., 2006; Payen et al., 2008;Mizuno et al., 2009; Ait Saada
et al., 2018). PARPi therefore increase the degree to which cancer
cells are reliant on core and regulatory HR factors. Deficiency in
HR related proteins such as BRCA1/2 then when combined with
a PARPi result in unrepaired lesions which can lead to apoptosis
and/or mitotic defects and death via mitotic catastrophe.
Limitations of PARPi
PARP inhibition is providing positive results in the clinic.
However, like any advancement made in oncology, there are
limitations. Firstly, PARP trapping by inhibitors compounds
the catalytic inhibition of the PARP enzyme, increasing their
potency. However, different PARP inhibitors exert the PARP
trapping effect to varying degrees and it can result in off-target
PARP trapping on the DNA of healthy tissue (Hopkins et al.,
2019). How to best optimize this for therapeutic gain is yet
to be fully determined. Secondly, various PARP inhibitors have
differential affinities for other PARP’s, posing a challenge for
therapeutic specificity. Finally, there is the emergence of PARP
inhibitor resistance within the clinic. Potentially underlying
mechanisms have been identified using pre-clinical models.
These mechanisms briefly include increased expression of drug
efflux proteins (Rottenberg et al., 2008; Vaidyanathan et al., 2016),
loss of PARP trapping (Gogola et al., 2018; Pettitt et al., 2018),
restoration of HR (Bouwman et al., 2010; Bunting et al., 2010;
Jaspers et al., 2013; Ter Brugge et al., 2016; Goodall et al., 2017;
Dev et al., 2018; He et al., 2018; Mirman et al., 2018; Noordermeer
et al., 2018) and replication fork stabilization (Chaudhuri et al.,
2016; Taglialatela et al., 2017; Murai et al., 2018) (Table 1). Given
these limitations, additional drug targets that are effective against
BRCA proficient and deficient tumors or indeed, even against
PARP inhibitor resistant tumors, are needed. One promising
target of interest is poly(ADP-ribose) glycohydrolase (PARG).
PARG – THE PRIMARY MEDIATOR OF
PAR CATABOLISM
Enzymology and Catalysis
Poly (ADP-ribose) glycohydrolase is the primary hydrolase
involved in the degradation of PAR (Figure 1) (Miwa and
Sugimura, 1971; Miwa et al., 1974; Lin et al., 1997).
PARG possesses both endo-glycohydrolase and exo-
glycohydrolase activity, preferentially performing the latter
by binding to the two most distal ADP-ribose residues within
the PAR chain (Brochu et al., 1994; Barkauskaite et al., 2013).
These different modes of catalysis produce free PAR and mono
ADP-ribose moieties, respectively. The free mono ADP-ribose
is then metabolized into AMP and ribose 5′ phosphate by
ADP-ribose pyrophosphohydrolases such as the NUDIX family
(Mildvan et al., 2005; McLennan, 2006; Palazzo et al., 2015). AMP
is utilized in ATP reformation and different metabolic and cell
signaling pathways (Rodríguez-Vargas et al., 2019) while ribose
5′ phosphate is a precursor to many biomolecules including
DNA, RNA and ATP (Kowalik et al., 2017). Endo-glycohydrolase
activity is considered to occur primarily during hyper-PARP
activation, the resulting free PAR chains produced are then
implicated in apoptosis acting as a death signal (Andrabi et al.,
2008). PARG itself specifically catalyzes the hydrolysis of α(1′′–2′)
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TABLE 1 | PARP inhibitor resistance mechanisms.
Resistance
mechanism
Cause of resistance Pre-clinical and clinical observations References
HR
restoration
BRAC1/2 Reversion restoring
HR
Mutations in patient tumors and PDX models treated with
PARPi, reversion mutations in BRCA1 and BRCA2 occur
frequently in patients with PARPi-resistant cancers
Ter Brugge et al., 2016; Goodall et al., 2017
Demethylation of
hypermethylated BRCA1
promoter
PDX models treated with PARPi Ter Brugge et al., 2016
Loss of 53BP1 Low expression and mutations in BRCA1 deficient PDX
models
Bouwman et al., 2010; Bunting et al., 2010
Loss of Shieldin factors Low expression and Mutations in BRCA1 deficient PDX
model
Dev et al., 2018; Noordermeer et al., 2018
Loss of CTC/Pola In vitro observations that phenocopy 53BP1 loss Mirman et al., 2018
Loss of DYNLL1/ATMIN In vitro reports that partially phenocopy 53BP1 loss He et al., 2018
Stalled fork
stabilization
Loss of PTIP, SLFN11 and
SMARCAL1
In vitro reports of loss inducing PARPi resistance in
BRCA1/2 deficient cells
Chaudhuri et al., 2016; Taglialatela et al., 2017;
Murai et al., 2018
Loss of EZH2 In vitro reports of loss inducing PARPi resistance in BRCA2
deficient cells
Rondinelli et al., 2017
Loss of
PARP
trapping
Mutation in PARP In vitro reports of mutations in PARP that induce resistance
in BRCA2 deficient cells, PARP1 mutation (R591C) which
prevents trapping found in a de novo PARPi resistant
patient tumor
Pettitt et al., 2018
Loss of PARG In vitro PARG depletion can cause PARPi resistance in
BRCA2−/− background
Gogola et al., 2018
Increased
drug efflux
ABC transporter upregulation PARPi resistance in vitro and in mouse models Rottenberg et al., 2008; Jaspers et al., 2013;
Vaidyanathan et al., 2016
or α(1′′′–2′′) glycosidic linkages (Figure 1). Although PARG
is the primary PAR hydrolase, some redundancy with the less
efficient ADP-ribosylhydrolase 3 (ARH3, also called ADPRHL2)
has been reported (Mueller-Dieckmann et al., 2006; Oka et al.,
2006; Fontana et al., 2017). Interestingly, other studies indicate a
unique function for ARH3 in degradation of mitochondrial PAR
(Niere et al., 2012). A more comprehensive review on other PAR
and MAR hydrolases can be found in O’Sullivan et al. (2019).
The PARG Isoforms – Subcellular
Localization and Domain Architecture
The human PARG gene is located at a single chromosomal
locus 10q11.23-21 (Shimokawa et al., 1998; Ame et al., 1999).
However, the PARG gene transcription product is subject
to alternative splicing, producing different PARG isoforms
(Figure 4) with distinct subcellular localization (Meyer-Ficca
et al., 2004). PARG111 is the largest isoform and contains four
domains: an intrinsically disordered regulatory region, a hinge
domain, the PARG catalytic domain and a macrodomain. It is
the primary nuclear PARG and has been reported to translocate
to the cytoplasm. PARG 102 and 99 lack part of the N-terminal
domain and possess a greater degree of whole cell activity. They
have a cytoplasmic and perinuclear distribution and have been
observed to translocate to the nucleus (Winstall et al., 1999),
particularly during genotoxic insult (Haince et al., 2006). The
details of how the shuttling of different isoforms fully contributes
to PAR metabolism and its significance is yet to be elucidated.
Mitochondrial PARG55 and PARG60 lack catalytic activity
(Meyer et al., 2007; Whatcott et al., 2009; Niere et al., 2012).
Functions have yet to be attributed to them. We hypothesize they
may have a PAR binding/regulatory role that is independent of
catalytic activity. Deletion of the PARG gene results in embryonic
lethality in mice making study of PARG by complete genetic
deletion difficult (Koh et al., 2004). Homozygous deletion of
PARG in exons 2 and 3 results in a deletion of the PARG110
isoform (equivalent to human 111 isoform) and is tolerated
in animals (Cortes et al., 2004). The manner in which the
rest of the exons are distributed across isoforms means other
genetic manipulations, selectively removing other isoforms, have
not been possible.
PARG INHIBITORS
Most PARG studies have until recently relied on hypomorphic
variants of PARG or RNAi-mediated depletion to examine
function. Development of PARG inhibitors (PARGi) has been late
compared to PARPi. Early inhibitors were restricted to a large
naturally occurring polyphenol, gallotannin, or rhodanine-based
inhibitors. However, increasingly cell permeable and specific
PARG inhibitors have recently been developed (Table 2). These
cluster into three types, quinazolinedione-type (PDD00017273),
naphthalen-type (COH34) and thioxanthine/methylxanthine
derivatives (JA2-4 and JA2131). All compete for PAR in the
PARG active site (James et al., 2016; Chen and Yu, 2019; Houl
et al., 2019). These inhibitors have helped elucidate function.
Regardless, an analogous problem remains that all the inhibitors
developed to date, work by inhibiting all catalytically active PARG
isoforms. The significance of inhibiting some or all of the PARG
isoforms has yet to be explored.
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FIGURE 4 | PARG isoforms are the product of a single gene and alternative splicing. PARG111 contains all the exons, PARG 102 lacks exon 1, and PARG99 lacks
exon 1 and 2. PARG60 has exons 1a, 4 and 6-18. PARG55 is the same but lacks exon 1a. PARG60 and 55 lack exon 5 rendering them catalytically inactive.
TABLE 2 | PARG inhibitors.
Inhibitor PARG IC50 Notes References
Gallotannin 16.8 µM Low activity, off-target effects Tsai et al., 1991
Rhodanine-based inhibitors (Rhodanine scaffold shown) 1–6 µM Specific, not cell-permeable Finch et al., 2012
GPI-16552 1.7 µM Low activity, off-target effects Lu et al., 2003
ADP-HPD 120 nM Specific, not cell-permeable Slama et al., 1995
PDD00017273 26 nM Specific, cell-permeable, lacks bioavailability James et al., 2016
COH34 0.37 nM Specific, potent, cell-permeable, 3.9 h half-life in vivo Chen and Yu, 2019
JA2131 400 nM Specific, cell-permeable, similarity to caffeine suggests bio-availability Houl et al., 2019
PARG FUNCTIONS IN DNA REPAIR
The consensus opinion in PAR biology is that PARP and PARG
co-operate to facilitate downstream cellular processes. Like PARP,
PARG loss and inhibition sensitizes cells to DNA damaging
agents, and it is likely that the function of PARG is to work with
various PARP proteins to facilitate an appropriate and timely
DNA repair. However, distinct functions should not be ruled out.
Single Strand Break Repair
PARG has been implicated in SSBR by both potentiating the
number of SSBs (Zhou et al., 2010) and reducing repair kinetics
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(Fisher et al., 2007; Ame et al., 2009; Min et al., 2010; Chen
and Yu, 2019). PARG depletion reduced the repair kinetics
of hydrogen peroxide induced SSBs. Concomitant depletion of
PARP1 did not further reduce the repair kinetics (Fisher et al.,
2007). This suggests PARP1 and PARG act in the same pathway
to promote SSBR. Following the induction of SSBs, PARP1/2
senses the damage, auto-PARylates itself and recruits XRCC1 to
the damaged site (Figure 2). XRCC1 then recruits the rest of the
SSBR factors finalizing the repair of the lesion. It is suggested that
removal of PAR is required to allow efficient repair (Figure 5). In
support of this, auto-modified PARP1 accumulated and persisted
at sites of SSBs when PARG was inhibited or depleted (Wei et al.,
2013; Gogola et al., 2018). Furthermore, XRCC1 was retained
at these same sites for longer (Fisher et al., 2007; Wei et al.,
2013; Chen and Yu, 2019). Interestingly, mouse cells deficient in
exon 2 and 3 of PARG resulted in fewer XRCC1 foci formation
in response to methylnitronitrosoguanidine (MNNG) treatment
(Gao et al., 2007). This suggests there may be a relationship
between the nuclear PARG isoform and XRCC1. In support of
this, PAR removal has been demonstrated to facilitate XRCC1
translocation from PAR directly to the SSB (Wei et al., 2013)
and if PARG activity is compromised then it may reduce the
efficiency at which this can occur. This may partially explain
the reduced repair kinetics. It is also possible that persistence
of PARP1 and XRCC1 at damage sites limits the availability
of these molecules for repair at other sites. It is likely in the
absence of dePARylation, PARP1 complexes bound to SSBs serve
as a lesion themselves. Furthermore, it is likely that these lesions
could act to form a barrier to replication and thus result in
stalled or collapsed replication forks (Figure 5). Support for this
comes from PARGi treated cells where increased levels of DNA
damage were dependent on replication (Fathers et al., 2012).
Furthermore, PARG deficient −/− embryonic stem cells and
PARG depleted pancreatic cancer cells exhibited S-phase arrest
and increased DNA damage when treated with the alkylating
agent MMS (Shirai et al., 2013b). As PARG is recruited to PAR via
its macrodomain, it is not clear whether when PARG is inhibited
PARG protein remains bound to PAR.
Double Strand Break Repair, Replication,
and Replication Fork Stability
The relationship between PARG and DSBR is poorly understood
but given the key role various PARPs play in the regulation
of DSBR, it is likely that reversal of PARP1-3 activity during
HR, alt-EJ and/or NHEJ by PARG is important for accurate
repair (Figure 5). Indeed, PARG depletion and inhibition have
both been shown to slow the repair kinetics of radiation-
induced DSBs with changes in both HR and NHEJ reported
(Ame et al., 2009; Gravells et al., 2018; Chen and Yu, 2019).
However, problems with replication can lead to forks collapsing
into DSBs, and with PARPs playing a prominent role in
maintaining fork stability, separating a role for PARG in DNA
replication and a role in DSBR is difficult. Interpretation
of experiments is further compounded by the finding that
a marker of HR at DSBs, RAD51, can also be a signal
for fork stabilization and HR mediated restart of replication
forks (Bhattacharya et al., 2017), while a marker of DSBs
53BP-1 is also known to be involved in fork protection
(Her et al., 2018).
The first study to suggest PARG is associated with replication
showed that following hydroxyurea (HU)-induced replication
stress, PARG110 deficient mouse cells display increased and
prolonged RAD51 foci formation (Min et al., 2010). More
direct evidence suggesting PARG111 has a role in DNA
replication comes from its association with proliferating cell
nuclear antigen (PCNA). GFP-tagged PARG111 co-localizes
with PCNA throughout S-phase while the 102 and 99
PARG isoforms do not. Immunoprecipitation confirmed the
N-terminal residues mediated an interaction (Mortusewicz
et al., 2011). Kaufmann et al. (2017) later confirmed this
N-terminal sequence was indeed important for replication foci
association, however, the interaction was primarily mediated
via the acetylation of a non-canonical PIP box in exon
3 of PARG (Kaufmann et al., 2017). This explains why
co-immunoprecipitation of the PARG102/99 isoforms with
PCNA was present although substantially reduced relative to
PARG111 (Mortusewicz et al., 2011). We hypothesize that
preventing PARG K409 acetylation or disrupting the protein-
protein interaction with PCNA could be exploited to specifically
target the nuclear PARG111 isoform. It is unclear whether
the PARG/PCNA interaction is integral to replication in an
unchallenged environment or whether it only has function during
replication stress.
PARG depletion increased the levels of PAR following chronic
but not transient HU-induced replication stress (Illuzzi et al.,
2014). Increased PAR was associated with reduced levels of
chromatin bound and phosphorylated RPA. We can therefore
hypothesize that excessive PAR can prevent RPA binding to
collapsed but not stalled replication forks. Further support for
a function for PARG during replication stress comes from
analyzing single replication forks using electron microscopy
and DNA fiber assays (Ray Chaudhuri et al., 2015). In this
study, PARG depletion slowed replication forks and increased
the number of reversed replication forks (Ray Chaudhuri et al.,
2015). There was also an increase in S-phase associated γH2AX
staining, a strong ATM and ATR signal and an increase in
chromatin binding of RAD51 and 53BP1. However, there were
no detectable DSBs by pulsed field gel electrophoresis. The
recruitment of these repair proteins in a context where there
were no detectable DSBs suggests that their recruitment is
to facilitate their replication associated functions. Thus, when
PARG is compromised, there may be a reliance on replication
fork protecting/restart factors. This may explain why PARPi
resistant cells with partially restored HR activity due to 53BP1
mutations are sensitive to PARG inhibitors (Chen and Yu,
2019). Consistent with PARG depletion, PARG inhibition also
slowed forks and increased fork stalling as shown by the
DNA fiber assay, and led to increased γH2AX and RAD51
foci formation on chromatin (Gravells et al., 2017; Houl
et al., 2019), adding further evidence for a function of PARG
during replication.
Although reduced PARG function leads to perturbed
replication, the precise function of PARG is not clear. PARP
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FIGURE 5 | Potential consequences of PARG inhibition (compared to PARP inhibition). Loss of dePARylation leads to increased PAR levels on PARP and other
acceptor proteins. This may prevent dissociation of PAR binding proteins preventing downstream processing and/or trap PARP on DNA forming further lesions
perturbing replication and leading to S/G2 phase arrest. If instability at replication forks persists or in the presence of DSBs cells will undergo apoptosis or mitotic
catastrophe. In this context both synthetic lethality with compensatory pathways needed to maintain replication integrity (HR and replication complex proteins) and
radio- and chemosensitization can occur. In addition it is likely that prolonged PARylation of other acceptor proteins modifies their function and impacts on cell
behavior including survival. (A) When PARG is inhibited hyper-PARylated PARP1/2 and XRCC1 accumulate at DNA single strand breaks such that single strand
break repair (SSBR) cannot proceed. In addition trapped PARP will form a lesion, which is likely to perturb replication. PARP inhibition traps unmodified PARP at
SSBs which slows repair and also collapses/stalls replication. (B) Activated PARP promotes collapsed fork restart, it is possible that reversal of PARylation on PARP
is required for fork restart (by homologous recombination (HR)) such that PARG inhibition prevents restart. PARP inhibition also prevents fork restart at collapsed
forks. (C) PARG inhibition leads to accumulation of reversed forks following replication stress likely because RECQ1 (Q1) remains PARylated and thus cannot
promote branch migration for replication restart. This is in contrast to PARP inhibition where reduced levels of reversed forks are seen. (D) PARG inhibition leads to
an increase in unligated Okazaki fragments. Analogous to SSBR it is likely that hyper-PARylated PARP accumulates XRCC1 but prevents downstream ligation of
okazaki fragments leading to replication fork instability. PARP inhibition slows ligation of fragments. (E,F) PARG inhibition combined with DNA damage induced
double strand breaks (DSB) is likely to lead to trapped hyper-PARylated PARP on DNA repair substrate intermediates and increased PARylation of KU80 and CHK2,
altering downstream repair of DNA and resulting in mitotic defects. PARP1/2 inhibition causes increased NHEJ. (G) PARG inhibition leads to mitotic defects including
fragmentation and amplification of centrosomes, multipolar spindles, chromosomal misalignment and aberrant segregation of chromosomes. This is likely due to
unrepaired DNA damage persisting into mitosis (see above) and lack of reversal of tankyrase (TNK1) and PARP3 dependent-PARylation during mitosis. E.g., during
mitosis PARP3 stimulates TNK activity increasing auto-ribosylation and ribosylation of NuMA to coordinate spindle dynamics. It is possible that in the absence of
dePARylation mitosis cannot progress, and that in the presence of exogenous DNA damage or inhibition of checkpoint signaling cells die of mitotic catastrophe.
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is reported to both protect transiently stalled replication forks
from collapse and mediate collapsed fork restart (Bryant et al.,
2009; Petermann et al., 2010; Ying et al., 2016). It is possible
that as with SSBR, removal of PAR from PARP is required to
facilitate the downstream steps of fork restart, although no direct
evidence for this exists (Figures 3, 5). In addition, dePARylation
of other proteins may be important. RECQ1 is a replication
fork associated helicase involved in replication fork restart
following fork reversal at sites of stalling (Popuri et al., 2012).
PARP1 PARylates RECQ1 inhibiting its action and preventing
premature fork restart and fork collapse (Ray Chaudhuri
et al., 2012; Berti et al., 2013). RECQ1 and PARG depletion
phenocopied each other to prevent fork restart in telomeric
DNA suggesting a function for PARG in reversing RECQ1
inhibition (Margalef et al., 2018). It is not known whether PARG
regulates RECQ1 activity in non-telomeric DNA. However, if
it occurs, lack of PARG during DNA replication could lead to
destabilization of reversed forks and an increased requirement
for fork protection factors to prevent collapse (Figures 3, 5).
This may partially explain why fork protection factors are
recruited to chromatin in a PARG deficient background (Ray
Chaudhuri et al., 2015). Further evidence of the importance
of PARG during replication stress comes from ovarian cancer
cells where loss of expression of key replication proteins
(e.g., Timeless, Hus1 and RFC2), led to sensitivity to PARGi
(Pillay et al., 2019).
Ray Chaudhuri et al. (2015) reported an increase in post
replicative single stranded gaps following PARG depletion. This
might be attributable to PARP1’s recently characterized function
in sensing unligated Okazaki fragments (Figure 3) (Hanzlikova
et al., 2018), and an as yet uncharacterised requirement for
dePARylation for ligation to proceed. PARG depletion may
therefore result in these PARylated Okazaki fragments being
unresolved leading to post replicative single stranded gaps.
Retention of XRCC1 at SSB sites is dependent on its BRCTII
domain (Wei et al., 2013). Ligase III also contains a BRCTII
domain and is involved in Okazaki fragment ligation. We
hypothesize that ligase III could get trapped at PARylatedOkazaki
fragments, analogous to XRCC1 at SSBs (Figure 5).
Finally, PARP has also been shown to recruit XRCC1 to a
subset of stalled (unresected) replication forks as a prerequisite
for fork restart (Figure 3) (Ying et al., 2016). As above it is
possible that PARG has a role in releasing PARP and XRCC1
so that fork restart can proceed (Figure 5), providing a second
mechanism by which PARG depletion could lead to increased
levels of reversed forks (Ray Chaudhuri et al., 2015). However,
only a small reduction in stalled fork restart is seen in the
absence of XRCC1 suggesting this function only mediates repair
of a subset of stalled forks, perhaps where small lesions impede
re-start of the forks.
In summary, evidence points to PARG having function in
SSBR, DSBR and during replication (Figures 2, 3). It is likely
that in many cases its role is to turn off PARP mediated function
to ensure correct timing of the subsequent steps in each repair
pathway. Thus, loss or inhibition of PARG will lead to altered
DNA repair (Figure 5). Furthermore, if PARylation persists, the
lesion formed is likely to act as a source of further DNA damage.
Other Functions of PARG Contributing to
PARGi-Mediated DNA Damage
Sensitivity
There are additional mechanisms that could result in the
observed DNA damage sensitization phenotypes. Activation of
PARP following DNA damage leads to changes in chromatin
structure due to PARylation of histones (Poirier et al., 1982).
The negative charge of PAR decompacts the histone complex
around chromatin, increasing its openness and accessibility;
lack/inhibition of PARG could prolong this state and leave
DNA more susceptible to DNA damage. In support of this,
PARG null trophoblastic stem cells have been reported to keep
chromatin decondensed and consequently increased the degree
of intercalation by acridine orange and alkylation by MNNG
and thymine basemodifications into cyclobutane pyridine dimers
induced by ultra violet (UV) light (Zhou et al., 2010; Koh, 2011).
Thus, a function of PARG may be to limit the length of time
chromatin is open, in order to maintain genomic stability.
Another function for PARG during DNA repair could
involve regulating NAD+ consumption. Once activated by
DNA damage, PARP uses cellular NAD+ as a substrate
which is normally and rapidly recycled by PARG (Figure 1).
However, upon excessive DNA damage, hyperactivation of
PARP can cause cellular NAD+ and thus ATP to be
depleted from cells and eventually result in mitochondrial
membrane destabilization and the release of apoptosis inducing
factors (AIF) to the nucleus (Yu et al., 2006; Stein and
Imai, 2012). AIF translocation culminates in AIF-mediated
apoptosis and DNA fragmentation (Yu, 2002) [reviewed
in Robinson et al. (2019)]. Unsurprisingly given PARG’s
role in PAR catabolism, loss of PARG exacerbates this
form of AIF mediated caspase independent apoptosis named
“parthanatos” (Zhou et al., 2011). Increased parthanatos has
been reported in MNNG or UV treated PARG deficient
backgrounds in vitro in breast cancer (Feng et al., 2012). This
suggests following DNA damage another function of PARG is to
suppress cell death.
PARG in Mitosis
PARG depleted cells have evidence of mitotic defects, including
fragmentation and amplification of centrosomes, multipolar
spindles, chromosomal misalignment and aberrant segregation
of chromosomes (Ame et al., 2009; Min et al., 2010). Further,
PARG is enriched at spindles in Xenopus extracts (Chang et al.,
2004). PARP1 null cells exhibit centrosome dysfunction and
amplification (Kanai et al., 2003), and PARP1 and 2 localize to
centromeres interacting with CENPA, CENPB, and Bub3 (Saxena
et al., 2002). TNK1 and/or PARP3 depletion leads to spindle
defects due to alteration in NuMA activity (Boehler et al., 2011).
Thus PARG may co-operate with multiple PARP enzymes to
regulate accuratemitosis. Consistent with this, after DNAdamage
PARGi led to spindle defects and the accumulation of cells
at metaphase. Interestingly, TNK inhibition but not PARP1-3
inhibition, phenocopied the spindle defects (Gravells et al., 2018),
highlighting the potential differences in mechanism of action of
PARPi and PARGi.
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TABLE 3 | Classes of DNA damage PARG depletion or inhibition alters cellular toxicity to.
Class of DNA
damage
Method of targeting PARG Experimental
system
Agent References
Alkylating agents Homozygous deletion of PARG exons 2 and 3 (selective
deletion of PARG110)
In vivo MNU (N-Methyl-N-
nitrosourea)
Streptozotocin
Cortes et al., 2004
PARG −/− mouse ES cells In vitro MNNG (methyl-
nitronitrosoguanidine)
Koh et al., 2004
PARGi (GPI 16552) in metastatic melanoma cancer cells In vitro and In vivo Temozolomide Tentori et al., 2005
PARGi (Gallotannin) in CHO cells In vitro MNNG Keil et al., 2004
PARG −/− mouse ES cells In vitro Dimethyl Sulfate Fujihara et al., 2009
PARG null mouse TS cells In vitro MNNG Zhou et al., 2010
Cyclo-
phosphamide
Hypomorphic mutation of PARG leading to PARG110 −/−
mouse embryonic fibroblasts
In vitro MMS (methyl
methanesulfonate)
Min et al., 2010
PARG −/− ES Cells and siRNA in human MIAPaCa2
(pancreas) and RKO (Colon) cancer cell lines
In vitro MMS Shirai et al., 2013b
PARGi (PDD00017273) in MCF7 breast cancer cells In vitro MMS James et al., 2016
PARGi – COH34 in various cancer cell lines In vitro Temozolomide Chen and Yu, 2019
Cross linking
agents
PARG −/− mouse ES cells In vitro Cisplatin Fujihara et al., 2009
PARG null mouse TS cells In vitro Cisplatin Zhou et al., 2010
PARG −/− ES Cells and siRNA in human MIAPaCa2
(pancreas) and RKO (Colon) cancer cell lines
In vitro Cisplatin Shirai et al., 2013b
PARGi (COH34) in various cancer cell lines In vitro Cisplatin Chen and Yu, 2019
PARGi (PDD00017273) and shRNA in PDAC cell lines In vitro and in vivo Oxaliplatin Jain et al., 2019
DNA metabolism PARG −/− mouse ES cells In vitro Gemcitabine Fujihara et al., 2009
PARGi (PDD00017273) in ovarian cancer cell lines In vitro Gemcitabine Pillay et al., 2019
HU
PARGi – (PDD00017273) and shRNA in PDAC cell lines. In vitro 5-Fluorouracil Jain et al., 2019
Intercalators PARG null mouse TS cells In vitro Epirubicin Zhou et al., 2010
PARGi (COH34) in various cancer cell lines In vitro Doxorubicin Chen and Yu, 2019
Incorporated
nucleotide analogs
PARG −/− mouse ES cells In vitro Gemcitabine Fujihara et al., 2009
PARGi (PDD00017273) in ovarian cancer cell lines In vitro Gemcitabine Pillay et al., 2019
Oxidative damage siRNA in MEFs In vitro Hydrogen peroxide Blenn et al., 2006
siRNA in A549 cancer cell line In vitro Hydrogen peroxide Fisher et al., 2007
Hypomorphic mutation of PARG leading to PARG110 −/−
mouse embryonic fibroblasts
In vitro Hydrogen peroxide Min et al., 2010
Radiation Homozygous deletion of PARG exons 2 and 3 (deletion of
PARG110)
In vivo γ-Irradiation Cortes et al., 2004
PARG−/− mouse ES cells In vitro γ-Irradiation Fujihara et al., 2009
siRNA in HeLa cells In vitro X-irradiation Ame et al., 2009
Hypomorphic mutation of PARG leading to PARG110 −/−
mouse embryonic fibroblasts
In vitro γ-Irradiation Min et al., 2010
PARG−/− mouse ES Cells In vitro γ-Irradiation Shirai et al., 2013a
Carbon ion
irradiation
Fe-Ion Irradiaiton
siRNA, PARGi (PDD00017273) in MCF-7 breast cancer cell
line
In vitro γ-Irradiation Gravells et al., 2018
PARGi (JA2131) in prostate cancer PC3 cell line In vitro Irradiation Houl et al., 2019
Topoisomerases
inhibitors
PARG −/− mouse ES cells In vitro Camptothecin Fujihara et al., 2009
shRNA HeLa cell line In vitro Camptothecin Ray Chaudhuri
et al., 2015
PARGi – COH34 in various cancer cell lines In vitro Camptothecin Chen and Yu, 2019
Black indicates sensitization by depletion or inhibition, red indicates no difference in response.
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THE THERAPEUTIC TARGETING OF
PARG
Like PARP, PARG depletion and inhibition are reported to
have chemo and radiosensitisation effects (Table 3), in addition
synthetic lethality has been reported in some contexts including
HR deficiency. These observations are likely underpinned by
effects on DNA repair and replication.
Radiosensitisation
In vitro reports in mouse embryonic stem cells and different
cancer backgrounds where PARG has been silenced/depleted
have consistently produced increased sensitivity to ionizing
radiation (IR) (Ame et al., 2009; Min et al., 2010; Nakadate et al.,
2013; Shirai et al., 2013a). This is thought to be underpinned
by an increase in mitotic defects that culminate in mitotic
catastrophe and cell death (Ame et al., 2009; Nakadate et al.,
2013). These observations have been replicated with PARG
inhibitors (Gravells et al., 2018; Houl et al., 2019). Tankyrase
inhibition partially phenocopied PARGi promoting aberrant
spindles and radiosensitisation suggesting PARGi may at least
partially mediate its effects by preventing the reversal of tankyrase
activity (Gravells et al., 2018). Both PARP and PARG inhibition
delayed the resolution of IR induced RAD51 foci consistent
with PARG reversal of PARP activity (Gravells et al., 2018).
However, a report that TNK can PARylate CHK2 (Nagy et al.,
2016) to promote HR raises the possibility that lack of reversal
of TNK activity can also effect HR. Despite slower resolution
of RAD51 foci, PARG inhibition increased the speed at which
γH2AX foci were resolved compared to PARPi treated cells
(Gravells et al., 2018). This suggests that the DNA damage
induced by radiation is resolved quicker when PARG is inhibited.
A possible explanation for the increased resolution was the
increased IR-induced phospho-DNA-PK(S2056) foci reported
under PARGi versus PARPi (Gravells et al., 2018). Increased
numbers of DNA-PK foci can be indicative of an increase in
cNHEJ, and PARG inhibition could therefore be functioning to
promote cNHEJ by preventing reversal of PARP1/3 dependent
PARylations (Figure 5). Alternatively, TNK is reported to
PARylate DNA-PK to stabilize it (Dregalla et al., 2010) and
it is possible that inhibition of PARG increases total cellular
levels of DNA-PK altering the DNA repair equilibrium. Finally,
phospho-DNA-PK(S2056) can also accumulate at unresected
stalled replication forks (Ying et al., 2016), thus it is possible
that PARG inhibition potentiates radiation induced stalled forks
altering repair kinetics.
Chemosensitisation
The reported chemosensitising effects of PARG
depletion/deletion/inhibition are variable. The majority of
the reports indicate sensitisation to different classes of DNA
damaging agents (Table 3 and references there in). It is likely that
the chemosensitizing mechanism is through reversal of PARP1-3
function in SSBR and DSBR or via effects on replication, but this
has yet to be fully explored.
Synthetic Lethality
PARG has been reported to be synthetically lethal (SL) with
different genes that often undergo loss of function mutations in
cancer, enabling targeted cell death. PARGi or PARG depletion
has been observed to be synthetically lethal in BRCA2 depleted
and deficient breast cancer cells (Fathers et al., 2012; Gravells
et al., 2017). PARG inhibition caused an increase in replication
fork collapse and replication associated DNA damage (Fathers
et al., 2012; Gravells et al., 2017). Accordingly, increased levels
of RAD51 foci and HR were also observed. Like PARPi,
PARGi therefore seem to increase the reliance on HR for fork
stability/restart, hence lethality in a BRCA2 mutant background
(Fathers et al., 2012; Gravells et al., 2017). Synthetic lethality
has also be reported with other HR related proteins including
BRCA1, PALB2, FAM175A (ABRAXAS), and BARD1 in breast
cancer cells where a more specific PARGi, PDD00017273, was
used and on-target effects validated using two independent
PARG siRNA (Gravells et al., 2017). Synthetic lethality between
PARGi and BRCA1/2 was confirmed using PDD00017273 in
pancreatic cancer cells (Jain et al., 2019) and with a second
PARGi, COH34, in ovarian cancer cells (Chen and Yu, 2019).
In contrast, siRNA mediated depletion of PARG in BRCA1
and PTEN deficient/proficient cells with a different genetic
background has been reported to not be synthetically lethal (Noll
et al., 2016). It is possible the nature of the BRCA1 deficiency may
also be significant.
Interestingly, when screening ovarian cancer cell lines
for sensitivity to the PARGi PDD00017273, cells that were
differentially sensitive to PARG but not PARP inhibition were
identified (Pillay et al., 2019). These cells had a replication
catastrophe event upon PARGi (identified as pan-nuclear γH2AX
staining) which was not seen with the PARPi olaparib. This
suggests that low expression of key replication factors that
promote fork stabilization, may be a biomarker predictive of
PARGi effectiveness and that PARGi could be used as an
alternative to PARPi. Consistent with this, BRCA1 mutated cells
that had gained resistance to PARPi through loss of 53BP-1,
were still more sensitive to the PARGi COH34 than BRCA1
wildtype cells (Chen and Yu, 2019). PARGi has also been reported
to be synthetic lethal in XRCC1 depleted and deficient cells
(Martin et al., 2018). This suggests PARGi may have efficacy
in XRCC1 tumors; we can speculate that this is due to the
function of XRCC1 in stabilizing stalled forks. Furthermore,
PARG depletion via siRNA was reported to be synthetic lethal
with dual specificity phosphatase 22 (DUSP22) via suppression
of the mTOR/PI3k/AKT and an increase in the expression of
PUMA inducing increased apoptosis in lung cancer (Sasaki et al.,
2019). This requires validation with an inhibitor but suggests
that PARGi in tumors deficient in DUSP22 are viable targets for
PARGi and that other genetic targets that induce apoptosis may
be worth investigating.
THE ROLE OF PARG IN CANCER
The therapeutic potential of targeting PARylation using PARP or
PARG inhibitors alone or in combination with other therapies
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clearly has promise as an anti-cancer therapy. However, genetic
manipulation of PARP and PARG suggests that PAR levels can
also impact tumor induction and progression. The mechanisms
by which changes in PARP expression can induce tumor
formation and progression are well documented (reviewed in
Schiewer and Knudsen, 2014). However, it is far less clear
the role PARG plays having been reported to both promote
(Dai et al., 2019; Marques et al., 2019) and suppress (Molloy-
Simard et al., 2012) tumourigenesis. Genetic manipulation of
PARG has demonstrated roles in proliferation (Pan et al., 2012),
differentiation (Wang et al., 2019), metastasis (Li et al., 2012;
Pan et al., 2012; Marques et al., 2019) and angiogenesis (Pan
et al., 2012). It will be interesting to see if PARG inhibitors can
recapitulate any of these findings as this will greatly increase their
potential as cancer therapeutics.
Roles Outside of DNA Repair
Genetic manipulation of PARG suggests that PAR levels can
impact tumor induction and progression (Li et al., 2012; Molloy-
Simard et al., 2012; Pan et al., 2012; Dai et al., 2019; Marques
et al., 2019; Wang et al., 2019). Although changes in DNA
repair capacity certainly contribute to genomic instability and
therefore tumourigenesis, there are other likely impacts within
the cell when PARG is disrupted. PAR also mediates a wide
range of effects on transcription (reviewed in (Schiewer and
Knudsen, 2014)). Studies have primarily focused on PARP1,
however, altered PARylation as a result of changes in PARG
expression is also likely to have a transcriptional effect. In
support of this, PARG overexpression increased dePARylation of
SMAD2/3, increasing SMAD target gene transcription which was
in part responsible for the tumourigenic phenotype observed as
a result of PARG expression (Dahl et al., 2014; Marques et al.,
2019). In addition, PARG silencing decreased PARP1 and NF-
kB expression which influenced DC and T cell fate to promote
a more favorable CD4/CD8 ratio which could suppress tumor
formation (Wang et al., 2019). When PARP and PARG depleted
cells were transcriptionally profiled, each regulated both a unique
set of genes, however, in each case there was also a similar number
of overlapping genes. Interestingly for the common genes PARP
and PARG acted in a similar, rather than opposing, fashion to
regulate gene expression (Frizzell et al., 2009), suggesting that in
this context they may work in concert.
The function of PARG in maintaining cellular NAD+ in
the context of DNA repair has been discussed. In addition,
altered NAD+ homoeostasis will likely compromise many
aspects of metabolic signaling that influence tumor formation,
transcription, behavior, and survival.
DISCUSSION
In conclusion, like PARP, PARG has multiple and complex roles
in DNA repair and replication. Many are related to the reversal
of autoPARylation of PARP1-3, but removal of PAR from other
targets such as RECQ1 or TNK1/2 are emerging as important. In
addition, it is likely that PARG impinges on many other aspects
of tumor biology, via regulation of oncogenic signaling pathways.
A number of pre-clinical studies now demonstrate that PARG
inhibitors show promise as anti-cancer therapeutics, however,
our understanding of the consequences of PARG inhibition need
to further be refined and the identification of novel contexts
in which PARG has promise as a target for inhibition need
to be determined. Thus, despite more than 50 years of study,
PAR biology continues to yield interesting and therapeutically
significant results.
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